Quantum-Si Incorporated

Quantum-Si Incorporated (NASDAQ: QSI) is a life sciences firm focused on protein detection and analysis. The company has created a comprehensive solution that integrates hardware, consumables, and software, built around its proprietary single-molecule detection platform. This platform powers Next-Generation Protein Sequencing (NGPS), offering enhanced capabilities for advanced protein sequencing. This report provides an overview of the company’s key financial indicators, associated risks, technical analysis, valuation, target price, and a recommendation on the stock.

As per our previous US Dailies Report published on ‘QSI’ on 26^th Feb, 2025, Kalkine provided an ‘Speculative Buy’ stance on the stock at USD 1.46 based on fundamental analysis and the stock price has now moved by ~ 35.62% since then and is trading above resistance 2.

Noted below are the details of support and resistance levels provided in our previous report:

Rationale – Sell at USD 1.98

• Sluggish Revenue Growth Despite Product Launches: Although Quantum-Si reported an 84% year-over-year increase in revenue for the first quarter of 2025, the total revenue remained modest at just USD 842,000. This indicates that despite launching the Platinum® Pro and progressing with its commercialization, the company’s products have yet to gain broad market traction. The limited scale of revenue suggests that Quantum-Si is still in the early stages of monetizing its technology, and significant growth in top-line performance may take time, especially amid broader market headwinds in the life sciences sector.
• Persistent Operating Losses and Rising Expenses: Quantum-Si continues to operate at a substantial loss, with a net loss of USD 19.2 million in Q1 2025. While this was slightly improved from the USD 19.5 million loss in the same quarter last year, the company’s financial trajectory still reflects high cash burn. Total operating expenses rose to USD 25.6 million from USD 23.6 million a year earlier, driven by ongoing investments in product development and commercialization. Adjusted EBITDA also deteriorated year-over-year, signaling continued financial strain and the need for sustained funding support to execute its growth strategy.
• Market Uncertainty in the U.S.: The company acknowledged that macroeconomic challenges are impacting its domestic market, particularly due to uncertainty surrounding NIH funding and tariffs. These factors may be limiting purchasing activity among U.S. customers, which is a key market for Quantum-Si. As a result, even though there is international momentum, the difficulties in the U.S. could hinder the company's broader growth ambitions and affect the uptake of new technologies in the short term.
• High Dependence on Future Product Development: Quantum-Si’s future success is heavily reliant on the timely development and successful commercialization of upcoming technologies such as the Proteus™ Platform, v4 Sequencing Kit, and v3 Library Preparation Kit. While management has reaffirmed confidence in meeting development timelines, any delays or setbacks in product performance, regulatory clearance, or market acceptance could significantly impact the company’s ability to scale revenue and move toward profitability. This dependency introduces a degree of operational risk.
• Uncertain Path to Profitability: Despite a robust cash position of USD 232.6 million bolstered by a recent USD 50 million capital raise, the company’s path to profitability remains uncertain. The high cost structure, modest revenue, and negative adjusted EBITDA indicate that breakeven is still likely several years away. While management expects its cash runway to last into the second half of 2027, ongoing losses and variable gross margins suggest that Quantum-Si must execute flawlessly on commercialization and expand market penetration to avoid future dilution or funding pressure.

Valuation (Using EV/Sales Multiple)

Share Price Chart

Conclusion

QSi’s Q1 2025 results highlight ongoing financial and operational challenges, with minimal revenue of USD 842,000 despite new product launches and continued high operating losses. The company remains heavily reliant on future product development for growth, while facing macroeconomic headwinds in the U.S., including NIH funding constraints and tariff uncertainty. Rising expenses, negative adjusted EBITDA, and a still-uncertain path to profitability raise concerns about the company’s ability to scale meaningfully, even with a strong cash runway through 2027.

Based on the notional gains, valuation downside and price action stance, a "Sell" recommendation on Quantum-Si Incorporated (NASDAQ: QSI) has been given at the closing market price of USD 1.77 as on 21 May 2025 at 07:20 AM PDT.

Note 1: Past performance is not a reliable indicator of future performance.

Note 2: The reference date for all price data, currency, technical indicators, support, and resistance level is 21 May 2025. The reference data in this report has been partly sourced from REFINITIV.

Note 3: Investment decisions should be made depending on an individual's appetite for upside potential, risks, holding duration, and any previous holdings. An 'Exit' from the stock can be considered if the Target Price mentioned as per the Valuation and or the technical levels provided has been achieved and is subject to the factors discussed above.

Note 4: Target Price refers to a price level which the stock is expected to reach as per the relative valuation method and/or technical analysis taking into consideration both short-term and long-term scenario.

Note 5: ‘Kalkine reports are prepared based on the stock prices captured either from the London Stock Exchange (LSE) and or REFINITIV. Typically, both sources (LSE and or REFINITIV) may reflect stock prices with a delay which could be a lag of 15-20 minutes. There can be no assurance that future results or events will be consistent with the information provided in the report. The information is subject to change without any prior notice.’

Note 6: Dividend Yield may vary as per the stock price movement.